

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/6399299/giorgia-bodini-publications-by-citations.pdf>  
**Version:** 2024-04-03

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.  
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

90 papers	1,364 citations	20 h-index	34 g-index
110 ext. papers	1,686 ext. citations	3.6 avg, IF	4.36 L-index

#	Paper	IF	Citations
90	Characteristics of reflux episodes and symptom association in patients with erosive esophagitis and nonerosive reflux disease: study using combined impedance-pH off therapy. <i>American Journal of Gastroenterology</i> , <b>2010</b> , 105, 1053-61	0.7	163
89	Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease: a randomized controlled trial. <i>American Journal of Gastroenterology</i> , <b>2013</b> , 108, 1731-42	0.7	147
88	Esophagogastric junction contractility for clinical assessment in patients with GERD: a real added value?. <i>Neurogastroenterology and Motility</i> , <b>2015</b> , 27, 1423-31	4	69
87	Proton pump inhibitors: use and misuse in the clinical setting. <i>Expert Review of Clinical Pharmacology</i> , <b>2018</b> , 11, 1123-1134	3.8	60
86	Positive glucose breath testing is more prevalent in patients with IBS-like symptoms compared with controls of similar age and gender distribution. <i>Journal of Clinical Gastroenterology</i> , <b>2009</b> , 43, 962-6	3	56
85	Esophageal motility abnormalities in gastroesophageal reflux disease. <i>World Journal of Gastrointestinal Pharmacology and Therapeutics</i> , <b>2014</b> , 5, 86-96	3	49
84	Gastrointestinal involvement in systemic sclerosis. <i>Presse Medicale</i> , <b>2014</b> , 43, e279-91	2.2	43
83	Functional Heartburn Overlaps With Irritable Bowel Syndrome More Often than GERD. <i>American Journal of Gastroenterology</i> , <b>2016</b> , 111, 1711-1717	0.7	41
82	High-resolution manometry is superior to endoscopy and radiology in assessing and grading sliding hiatal hernia: A comparison with surgical in vivo evaluation. <i>United European Gastroenterology Journal</i> , <b>2018</b> , 6, 981-989	5.3	36
81	The natural history of gastro-esophageal reflux disease: a comprehensive review. <i>Ecological Management and Restoration</i> , <b>2017</b> , 30, 1-9	3	35
80	A review of pharmacotherapy for treating gastroesophageal reflux disease (GERD). <i>Expert Opinion on Pharmacotherapy</i> , <b>2017</b> , 18, 1333-1343	4	31
79	Development and Validation of a Test to Monitor Endoscopic Activity in Patients With Crohn's Disease Based on Serum Levels of Proteins. <i>Gastroenterology</i> , <b>2020</b> , 158, 515-526.e10	13.3	28
78	Impact of evidence-based medicine on the treatment of patients with unresectable hepatocellular carcinoma. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2010</b> , 31, 493-501	6.1	27
77	Mediterranean Diet and NAFLD: What We Know and Questions That Still Need to Be Answered. <i>Nutrients</i> , <b>2019</b> , 11,	6.7	27
76	Adalimumab trough serum levels and anti-adalimumab antibodies in the long-term clinical outcome of patients with Crohn's disease. <i>Scandinavian Journal of Gastroenterology</i> , <b>2016</b> , 51, 1081-6	2.4	26
75	Vonoprazan fumarate for the management of acid-related diseases. <i>Expert Opinion on Pharmacotherapy</i> , <b>2017</b> , 18, 1145-1152	4	25
74	Improvement in hepatitis C virus patients with advanced, compensated liver disease after sustained virological response to direct acting antivirals. <i>European Journal of Clinical Investigation</i> , <b>2019</b> , 49, e13056	4.6	24

73	The appropriate use of proton-pump inhibitors. <i>Minerva Medica</i> , <b>2018</b> , 109, 386-399	2.2	23
72	Novel Prognostic Biomarkers of Mucosal Healing in Ulcerative Colitis Patients Treated With Anti-TNF: Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio. <i>Inflammatory Bowel Diseases</i> , <b>2020</b> , 26, 1579-1587	4.5	21
71	Esophageal testing: What we have so far. <i>World Journal of Gastrointestinal Pathophysiology</i> , <b>2016</b> , 7, 72-85	3.2	20
70	Infliximab trough levels and persistent vs transient antibodies measured early after induction predict long-term clinical remission in patients with inflammatory bowel disease. <i>Digestive and Liver Disease</i> , <b>2018</b> , 50, 452-456	3.3	19
69	Comparison of Two Different Techniques to Assess Adalimumab Trough Levels in Patients with Crohn's Disease. <i>Journal of Gastrointestinal and Liver Diseases</i> , <b>2015</b> , 24, 451-6	1.4	19
68	Epidemiology and natural history of gastroesophageal reflux disease. <i>Minerva Gastroenterology</i> , <b>2017</b> , 63, 175-183	3	19
67	A randomized, 6-wk trial of a low FODMAP diet in patients with inflammatory bowel disease. <i>Nutrition</i> , <b>2019</b> , 67-68, 110542	4.8	18
66	Anti-TNF therapy is able to stabilize bowel damage progression in patients with Crohn's disease. A study performed using the Lfmann Index. <i>Digestive and Liver Disease</i> , <b>2017</b> , 49, 175-180	3.3	17
65	Gadolinium accumulation after contrast-enhanced magnetic resonance imaging: Which implications in patients with Crohn's disease?. <i>Digestive and Liver Disease</i> , <b>2017</b> , 49, 728-730	3.3	16
64	Surveillance for Hepatocellular Carcinoma in Patients with Non-Alcoholic Fatty Liver Disease: Universal or Selective?. <i>Cancers</i> , <b>2020</b> , 12,	6.6	16
63	A safety review of proton pump inhibitors to treat acid-related digestive diseases. <i>Expert Opinion on Drug Safety</i> , <b>2018</b> , 17, 785-794	4.1	16
62	Prevention of postoperative recurrence of Crohn's disease by Adalimumab: a case series. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2012</b> , 24, 468-70	2.2	16
61	Low Fibrinogen Levels Are Associated with Bleeding After Varices Ligation in Thrombocytopenic Cirrhotic Patients. <i>Annals of Hepatology</i> , <b>2018</b> , 17, 830-835	3.1	16
60	Vonoprazan for treatment of gastroesophageal reflux: pharmacodynamic and pharmacokinetic considerations. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , <b>2016</b> , 12, 1333-1341	5.5	15
59	Real-life effectiveness of ustekinumab in inflammatory bowel disease patients with concomitant psoriasis or psoriatic arthritis: An IGD study. <i>Digestive and Liver Disease</i> , <b>2019</b> , 51, 972-977	3.3	13
58	The Lyon Consensus: Does It Differ From the Previous Ones?. <i>Journal of Neurogastroenterology and Motility</i> , <b>2020</b> , 26, 311-321	4.4	13
57	Concerns related to COVID-19 pandemic among patients with inflammatory bowel disease and its influence on patient management. <i>European Journal of Clinical Investigation</i> , <b>2020</b> , 50, e13233	4.6	12
56	Low serum trough levels are associated with post-surgical recurrence in Crohn's disease patients undergoing prophylaxis with adalimumab. <i>Digestive and Liver Disease</i> , <b>2014</b> , 46, 1043-6	3.3	11

55	Optimal management of constipation associated with irritable bowel syndrome. <i>Therapeutics and Clinical Risk Management</i> , <b>2015</b> , 11, 691-703	2.9	10
54	Vegetal and Animal Food Proteins Have a Different Impact in the First Postprandial Hour of Impedance-pH Analysis in Patients with Heartburn. <i>Gastroenterology Research and Practice</i> , <b>2018</b> , 2018, 7572430	2	9
53	Vonoprazan Fumarate for the Treatment of Gastric Ulcers: A Short Review on Emerging Data. <i>Clinical and Experimental Gastroenterology</i> , <b>2020</b> , 13, 99-104	3.1	8
52	Reduction in TIMP-2 serum levels predicts remission of inflammatory bowel diseases. <i>European Journal of Clinical Investigation</i> , <b>2018</b> , 48, e13002	4.6	8
51	Activities related to inflammatory bowel disease management during and after the coronavirus disease 2019 lockdown in Italy: How to maintain standards of care. <i>United European Gastroenterology Journal</i> , <b>2020</b> , 8, 1228-1235	5.3	8
50	Patient and physician views on the quality of care for inflammatory bowel disease after one-year follow-up: Results from SOLUTION-2, a prospective IG-IBD study. <i>Digestive and Liver Disease</i> , <b>2017</b> , 49, 997-1002	3.3	7
49	Infliximab Originator, Infliximab Biosimilar, and Adalimumab Are More Effective in Crohn's Disease Than Ulcerative Colitis: A Real-Life Cohort Study. <i>Clinical and Translational Gastroenterology</i> , <b>2020</b> , 11, e00177	4.2	7
48	Antimicrobial treatment with the fixed-dose antibiotic combination RHB-104 for Mycobacterium avium subspecies paratuberculosis in Crohn's disease: pharmacological and clinical implications. <i>Expert Opinion on Biological Therapy</i> , <b>2019</b> , 19, 79-88	5.4	7
47	Translation and initial validation of the Medication Adherence Report Scale (MARS) in Italian patients with Crohn's Disease. <i>Digestive and Liver Disease</i> , <b>2019</b> , 51, 640-647	3.3	7
46	The role of small intestinal bacterial overgrowth in cystic fibrosis: a randomized case-controlled clinical trial with rifaximin. <i>Journal of Gastroenterology</i> , <b>2019</b> , 54, 261-270	6.9	7
45	Advancements in the use of manometry and impedance testing for esophageal functional disorders. <i>Expert Review of Gastroenterology and Hepatology</i> , <b>2019</b> , 13, 425-435	4.2	6
44	Adalimumab biosimilars, ABP501 and SB5, are equally effective and safe as adalimumab originator. <i>Scientific Reports</i> , <b>2021</b> , 11, 10368	4.9	6
43	Adalimumab trough levels and response to biological treatment in patients with inflammatory bowel disease: a useful cutoff in clinical practice. <i>American Journal of Gastroenterology</i> , <b>2015</b> , 110, 472-3 <sup>0.7</sup>		5
42	Nuts and Non-Alcoholic Fatty Liver Disease: Are Nuts Safe for Patients with Fatty Liver Disease?. <i>Nutrients</i> , <b>2020</b> , 12,	6.7	5
41	Appropriateness of proton pump inhibitors treatment in clinical practice: Prospective evaluation in outpatients and perspective assessment of drug optimisation. <i>Digestive and Liver Disease</i> , <b>2020</b> , 52, 862-868	3.3	5
40	Pathophysiology, diagnosis, and pharmacological treatment of gastro-esophageal reflux disease. <i>Expert Review of Clinical Pharmacology</i> , <b>2020</b> , 13, 437-449	3.8	5
39	Eradication of hepatitis C virus infection disclosing a previously hidden, underlying autoimmune hepatitis: Autoimmune hepatitis and HCV. <i>Annals of Hepatology</i> , <b>2020</b> , 19, 222-225	3.1	5
38	Corticosteroid Treatment at Diagnosis: An Analysis of Relapses, Disease Extension, and Colectomy Rate in Ulcerative Colitis. <i>Digestive Diseases and Sciences</i> , <b>2020</b> , 65, 2397-2402	4	5

37	Course of oesophageal varices and performance of noninvasive predictors following Hepatitis C Virus clearance in compensated advanced chronic liver disease. <i>European Journal of Clinical Investigation</i> , <b>2020</b> , 50, e13231	4.6	5
36	Granulocytes and monocytes apheresis induces upregulation of TGF $\beta$ in patients with active ulcerative colitis: A possible involvement of soluble HLA-I. <i>Journal of Clinical Apheresis</i> , <b>2017</b> , 32, 49-55	3.2	4
35	High anti-TNF alfa drugs trough levels are not associated with the occurrence of adverse events in patients with inflammatory bowel disease. <i>Scandinavian Journal of Gastroenterology</i> , <b>2019</b> , 54, 1220-1225	2.4	4
34	Treatment of early stage chronic hepatitis C virus infection. <i>Expert Review of Clinical Pharmacology</i> , <b>2018</b> , 11, 519-524	3.8	4
33	NASH-related and cryptogenic cirrhosis similarities extend beyond cirrhosis. <i>Journal of Hepatology</i> , <b>2018</b> , 69, 972-973	13.4	3
32	DOP057 The influence of anti-adalimumab antibodies on adalimumab trough levels, TNF- $\beta$ levels and clinical outcome. <i>Journal of Crohns and Colitis</i> , <b>2014</b> , 8, S42	1.5	3
31	Letter: biological therapies are effective for prevention of post-operative Crohn's disease recurrence. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2014</b> , 40, 322	6.1	3
30	Elevated adherence to vaccination against SARS-CoV-2 among patients with Inflammatory Bowel Disease. <i>Journal of Crohns and Colitis</i> , <b>2021</b> ,	1.5	3
29	A propensity score-weighted comparison between adalimumab originator and its biosimilars, ABP501 and SB5, in inflammatory bowel disease: a multicenter Italian study. <i>Therapeutic Advances in Gastroenterology</i> , <b>2021</b> , 14, 17562848211031420	4.7	3
28	Letter: faecal volatile organic metabolites, promising biomarkers in inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2016</b> , 43, 1240-1	6.1	2
27	Telemedicine and Remote Screening for COVID-19 in Inflammatory Bowel Disease Patients: Results From the SoCOVID-19 Survey. <i>Inflammatory Bowel Diseases</i> , <b>2020</b> , 26, e134-e136	4.5	2
26	Reproducibility and Transportability of the Absence of Incremental Infectious Adverse Events in Patients With Higher Anti-TNF Drug Levels. <i>Inflammatory Bowel Diseases</i> , <b>2019</b> , 25, e73	4.5	2
25	Harmonising proton pump inhibitors treatment in the specialist setting following the SIGE recommendations. <i>Digestive and Liver Disease</i> , <b>2019</b> , 51, 173-174	3.3	2
24	Two-year effectiveness and safety of golimumab in ulcerative colitis: An IG-IBD study. <i>United European Gastroenterology Journal</i> , <b>2021</b> , 9, 102-109	5.3	2
23	P576 Therapeutic drug monitoring as predictive marker of mucosal healing in Crohn's disease patients treated with anti-TNF: a prospective multi-centre study. <i>Journal of Crohns and Colitis</i> , <b>2019</b> , 13, S402-S403	1.5	1
22	A Closer Look at Factors Associated With Bleeding in Cirrhotic Patients. <i>American Journal of Gastroenterology</i> , <b>2019</b> , 114, 364-365	0.7	1
21	The placebo effect is a relevant factor in evaluating effectiveness of therapies in functional gastrointestinal disorders. <i>Journal of Gastroenterology</i> , <b>2014</b> , 49, 1362-3	6.9	1
20	A Nodule, is a Nodule, is a Nodule: May Alpha-Fetoprotein Make the Difference?. <i>American Journal of Gastroenterology</i> , <b>2017</b> , 112, 1340	0.7	1

19	Impedance-detected Symptom Association and Number of Reflux Episodes as Pre-treatment Parameters That Predict Outcomes of Gastroesophageal Reflux Disease Patients. <i>Journal of Neurogastroenterology and Motility</i> , <b>2015</b> , 21, 292-3	4.4	1
18	Anti-Tumor Necrosis Factor Antibodies for Prevention of Crohn's Disease Recurrence After Surgery: More Than a Hope. <i>Clinical Gastroenterology and Hepatology</i> , <b>2015</b> , 13, 1856	6.9	1
17	Not All Patients With Non-erosive Reflux Disease Share Psychological Distress as Main Mechanism of Disease. <i>Journal of Neurogastroenterology and Motility</i> , <b>2014</b> , 20, 129-30	4.4	1
16	Letter: predictive factors for treatment discontinuation in IBD-anti-TNF trough levels and anti-drug antibodies. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2021</b> , 54, 536-537	6.1	1
15	Tricyclic Antidepressants in Refractory GERD: Poorly Effective Drugs or Wrong Patients?. <i>American Journal of Gastroenterology</i> , <b>2016</b> , 111, 1037-8	0.7	1
14	Letter: biologics are effective in neutralising the detrimental effect of smoking on the natural course of Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2016</b> , 43, 1245	6.1	1
13	Applicability of Parameters for the Noninvasive Diagnosis of Esophageal Varices Needing Treatment to Hepatitis C Virus-Cured Patients. <i>Clinical Infectious Diseases</i> , <b>2021</b> , 72, 1862-1863	11.6	1
12	Bleeding after paracentesis in patients with decompensated cirrhosis and acute kidney injury: The perfect storm. <i>Liver International</i> , <b>2018</b> , 38, 2101	7.9	1
11	Therapeutic drug monitoring in Crohn's disease patients treated with anti-TNF: a comparison of two techniques. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2021</b> ,	2.2	1
10	Gastro-esophageal reflux disease: Key messages for clinicians. <i>Minerva Gastroenterologica E Dietologica</i> , <b>2020</b> ,	1.6	1
9	Long-term outcomes of acute severe ulcerative colitis in the rescue therapy era: A multicentre cohort study. <i>United European Gastroenterology Journal</i> , <b>2021</b> , 9, 507-516	5.3	0
8	P541 Real-life effectiveness of ustekinumab in inflammatory bowel disease patients with concomitant psoriasis or psoriatic arthritis: an IG-IBD study. <i>Journal of Crohns and Colitis</i> , <b>2019</b> , 13, S384-S385	1.5	1
7	Risk factors for bleeding following oesophageal band ligation: Providing further evidence to ameliorate clinical practice. <i>Digestive and Liver Disease</i> , <b>2020</b> , 52, 792-793	3.3	
6	Prevention of Crohn's disease recurrence after surgery: on the road to recovery. <i>Clinical Gastroenterology and Hepatology</i> , <b>2014</b> , 12, 1406	6.9	
5	Hepatocellular Carcinoma Intermediate Stage Subclassification Systems: One, None, and One Hundred Thousand. <i>Liver Cancer</i> , <b>2019</b> , 8, 524-526	9.1	
4	Regression of Fibrosis After Direct-acting Antivirals Treatment of Patients with Hepatitis C Virus Cirrhosis: Transposability to Nondecompensated Patients. <i>Journal of Clinical and Experimental Hepatology</i> , <b>2019</b> , 9, 546	4.1	
3	Proactive Measures Aimed at Improving Appropriateness of Use of Proton Pump Inhibitors in Clinical Practice. <i>Clinical Gastroenterology and Hepatology</i> , <b>2021</b> , 19, 410	6.9	
2	Letter: vedolizumab or a second anti-TNF-no difference in efficacy for primary biologic failures with IBD. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2021</b> , 53, 1044-1045	6.1	

- 1 Response to COVID-19 Vaccination in Patients with Inflammatory Bowel Disease on Biological Treatment. *Gastrointestinal Disorders*, **2022**, 4, 77-83 o.8